Invitation for presentation of Sedana Medical’s fourth quarter and Year-End Report 2021
Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2021 in an audiocast on February 17 at 13.30 CET.
According to the financial calendar, Sedana Medical plans to publish the fourth quarter and Year-End Report for 2021 on Thursday February 17 at approximately 07.00 CET. Sedana Medical hereby invites to a presentation of the report on the same day, where the CEO Johannes Doll will present the report in English together with Peter Sackey CMO and Linda Frölén, Head of Group Finance, as well as answer questions.
Date: Thursday February 17 2022
Time (CET): 13.30
Link to audiocast: https://financialhearings.com/event/43299
For additional information, please contact:
Johannes Doll, CEO, +46 (0)76 303 66 66
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, firstname.lastname@example.org.
About Sedana Medical
Sedana Medical AB (publ) is a pioneer medtech and pharmaceutical company focused on inhaled sedation to improve the patient’s life during and beyond sedation. Through the combined strengths of the medical device Sedaconda ACD and the pharmaceutical Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated patients in intensive care.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordic, and Spain. In other parts of Europe as well as in Asia, Australia, Canada, and South- and Central America, the company works with external distributors.
Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.